LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
Podcast: The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
University of Kansas
Headquarters:
Lawrence, KS, United States
Website:
http://www.ku.edu
Year Founded:
1865
Status:
Non-biopharma
Biopharma related deals can be found by searching the organization's name in the
Deals
Module.
BioCentury
|
Mar 28, 2024
Emerging Company Profile
Vandria: renewing mitochondria to treat CNS, muscle and other diseases
Swiss biotech Vandria is restoring energy balance in neurons with its first program, soon to enter the clinic for mild cognitive impairment
Read More
BioCentury
|
Apr 9, 2022
Finance
April 8 Quick Takes: Kaleido winding down operations
Plus: BioCryst loses $1.2B in market cap after pivotal pause and the latest in CEPI investments and more
Read More
BioCentury
|
Jun 13, 2020
Translation in Brief
OSE identifies myeloid checkpoint target; plus a call from NCI for COVID-19 test proposals, Sinopharm vaccine data and more
BioCentury’s roundup of preclinical news
Read More
BioCentury
|
Mar 29, 2019
Targets & Mechanisms
Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment
A look at new and emerging targets at AACR 2019 and their mechanisms
Read More
BioCentury
|
Mar 15, 2019
Product Development
Broadening the PARP playing field
How the PARP field is mapping out new synthetic lethality plays
Read More
BioCentury
|
Jan 25, 2019
Company News
Notable Labs grants Cures Within Reach commercial rights to pediatric leukemia compound
Read More
BioCentury
|
Aug 22, 2017
Preclinical News
AHA1 inhibition reduces tau accumulation
Read More
BioCentury
|
Aug 9, 2017
Distillery Techniques
Drug properties
Read More
BioCentury
|
Jun 27, 2017
Distillery Therapeutics
Renal
Read More
BioCentury
|
Dec 14, 2015
Product Development
Risk-benefit litmus test
How Zafgen could find an approval path after a second death in beloranib trials
Read More
Items per page:
10
1 - 10 of 60